Stock SplitsBy The Online Investor Staff, updated Fri., May. 24, 7:09 AM
|This Slide: #7 of 25|
Slide #7. Auris Medical Holding Ltd. (NASDAQ:EARS) — 1 for 20 Reverse Split
1 for 20
Auris Medical Holding is a clinical-stage biopharmaceutical company focused on the development of novel products for the treatment of inner ear disorders. Co.'s most advanced product candidate, AM-101, is in Phase 3 clinical development for acute inner ear tinnitus under a special protocol assessment, or SPA, from the FDA. In two recently completed Phase 2 clinical trials, AM-101 demonstrated a favorable safety profile and statistically significant improvement in tinnitus loudness and other patient reported outcomes. Co. is also developing AM-111 for acute inner ear hearing loss.
EARS Detailed Information Page & Split History »